Bifogade filer
Xbrane Interim report January - June 2022
Kurs
+5,80%
Likviditet
3,81 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2025-10-24 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-27 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-08 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-05-06 | N/A | X-dag ordinarie utdelning XBRANE 0.00 SEK |
| 2025-05-05 | N/A | Årsstämma |
| 2025-04-14 | - | Extra Bolagsstämma 2025 |
| 2025-02-21 | - | Bokslutskommuniké 2024 |
| 2024-10-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-28 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-16 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-03 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
| 2024-05-02 | - | Årsstämma |
| 2024-02-26 | - | Bokslutskommuniké 2023 |
| 2024-02-22 | - | Extra Bolagsstämma 2024 |
| 2023-11-30 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-29 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-31 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-05 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
| 2023-05-04 | - | Årsstämma |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-10-28 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-22 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-06 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
| 2022-05-05 | - | Årsstämma |
| 2022-05-05 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-10-29 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-13 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-07 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
| 2021-05-06 | - | Årsstämma |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-13 | - | Kvartalsrapport 2020-Q3 |
| 2020-09-22 | - | Extra Bolagsstämma 2020 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-22 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
| 2020-06-18 | - | Årsstämma |
| 2020-05-14 | - | Årsstämma |
| 2020-05-13 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-15 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-23 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-18 | - | Extra Bolagsstämma 2019 |
| 2019-05-17 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
| 2019-05-16 | - | Årsstämma |
| 2019-05-14 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-28 | - | Bokslutskommuniké 2018 |
| 2018-11-16 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-25 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
| 2018-05-14 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-03 | - | Extra Bolagsstämma 2018 |
| 2018-02-28 | - | Bokslutskommuniké 2017 |
| 2017-11-13 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-31 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-19 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
| 2017-05-18 | - | Årsstämma |
| 2017-05-18 | - | Kvartalsrapport 2017-Q1 |
| 2017-03-07 | - | Kapitalmarknadsdag 2017 |
| 2017-02-27 | - | Bokslutskommuniké 2016 |
| 2016-11-21 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-22 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-27 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
| 2016-05-27 | - | Kvartalsrapport 2016-Q1 |
| 2016-05-26 | - | Årsstämma |
| 2016-02-18 | - | Bokslutskommuniké 2015 |
| 2015-10-23 | - | Kvartalsrapport 2015-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Production being initiated for launch of Xlucane™ in Europe first quarter of 2023*
Xbrane Biopharma AB’s (publ.) (”Xbrane”) interim report for January - June 2022 is now available on the Company’s website, www.xbrane.com.
Financial overview second quarter 2022
- Revenue amounted to SEK 15.6 m (2.5).
- Other operating income was SEK 11.4 m (0.4).
- EBITDA amounted to SEK -28.4 m (-53.8).
- R&D costs amounted to SEK -52.9 m (-49.9) corresponding to 89% (84) of total operating costs.
- The net result for the period was SEK -33.8 m (-59.2).
- Earnings per share amounted to SEK -1.35 (-2.67).
- Cash and cash equivalents at the end of the period amounted to SEK 250.1 m (129.3).
Financial overview first half of 2022
- Revenue amounted to SEK 22.8 m (5.1).
- Other operating income was SEK 17.6 m (2.5).
- EBITDA amounted to SEK -61.3 m (-100.6).
- R&D costs amounted to SEK -88.9 m (-95.3) corresponding to 81% (84) of total operating costs.
- The net result for the period was SEK -69.9 m (-110.4).
- Earnings per share amounted to SEK -2.79 (-4.97).
- Cash and cash equivalents at the end of the period amounted to SEK 250.1 m (129.3).
Figures in parentheses refer to the corresponding period last year.
Significant events in the second quarter 2022
- In May, it was announced that the company had withdrawn its marketing authorization application for its LUCENTIS® biosimilar candidate following a request for additional information from the FDA (US equivalent to the Swedish Medicines Agency).
- At the end of June, a change in the number of shares and voting rights in Xbrane linked to a long-term share saving program, was announced.
Significant events after the end of the quarter
- In early July, an update was provided regarding supplements and recommendations received from the FDA. The application is planned to be resubmitted during 2022.
*) Production is initiated after the expiration of relevant patents
Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on July the 22nd, 2022, at 10.00 a.m. CET. See the link to the presentation below.
Contacts
Martin Åmark, CEO
M: +46 76 309 37 77
E: martin.amark@xbrane.com
Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E: anette.lindqvist@xbrane.com
About Us
Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting SEK 332 billion in annual sales of the respective reference products, with the leading one under registration in Europe. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com
This information is information that Xbrane Biopharma is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-07-22 08:00 CEST.